Semaglutide plus counseling most effectively reduces BMI in pediatric obesity, outperforming other pharmacotherapies
Background
Pediatric obesity is a significant global health challenge, with current health behavior and lifestyle treatments (HBLT) forming the foundational approach. However, the comparative effectiveness of HBLT alone, various pharmacotherapies, and their combinations remains unclear, creating a critical gap in optimizing treatment strategies for children and adolescents. Understanding which interventions, particularly novel agents like glucagon-like peptide-1 receptor agonists (GLP-1RAs), offer the best outcomes is crucial for improving weight management and long-term health in this vulnerable population.
Study Design
This systematic review and network meta-analysis synthesized data from 42 randomized clinical trials (RCTs) involving 3835 participants (aged 10-19 years) with obesity. Interventions included structured lifestyle treatment (HBLT and counseling), various obesity management pharmacotherapies (e.g., glucagon-like peptide-1 receptor agonists, metformin, orlistat, phentermine-topiramate), or their combination, compared against control groups. A random-effects network meta-analysis pooled data, with meta-regression exploring outcome moderators. Primary outcomes were BMI and BMI z score; secondary outcomes included waist circumference (WC), fat mass (FM), and lean mass (LM).
Results
Treatments combining pharmacotherapy and lifestyle treatment demonstrated the greatest efficacy across all adiposity-related outcomes in pediatric obesity. Specifically, semaglutide plus counseling was associated with the largest reductions. It achieved a mean difference of -8.31 (95% CI, -12.33 to -4.28) in
BMIand a mean difference of -1.80 (95% CI, -2.39 to -1.21) inBMI z score. This superior efficacy was observed across primary and secondary outcomes, includingWC,FM, andLM. The analysis included 42 RCTs with 3835 participants, with a median age of 14.5 years (59.2% female). All pharmacological treatments were more effective than lifestyle treatment alone, but the combination approach yielded the most significant improvements.
Why It Matters
Combination therapy, particularly with GLP-1RAs like semaglutide, should be considered a front-line strategy for pediatric obesity management. This research provides strong evidence that integrating pharmacotherapy with lifestyle counseling significantly enhances weight loss outcomes beyond what either approach achieves alone. For clinicians, this suggests a shift towards more aggressive, multi-modal interventions for youth struggling with obesity. While specific dosing protocols are not detailed here, the findings underscore the importance of semaglutide as a potent tool. Future protocols for pediatric obesity may increasingly feature GLP-1RAs alongside structured behavioral support, potentially leading to more effective and sustained weight management in adolescents.